HemaCare Corporation, a leading provider of cellular therapy services to healthcare providers and the scientific community, today announced that it will host a panel discussion comprised of the world’s leading experts in cell therapy at the International Society for Cellular Therapy’s (ISCT) 20th Annual Scientific Meeting in Paris, April 23-26.
As cell therapy products must be delivered without significant loss of viable, functional cells, stability and transport take on critical importance. The panel discussion, titled “Sourcing, Isolating, Preserving, Shipping, and Tracking Precious Human Biological Products: Global Solutions for Research and Cell Therapy,” will explore practical considerations for cell and tissue supply chains, including sourcing and characterization of cells for R&D and manufacturing, optimizing cell stability and extending product shelf life, and effective product shipping and tracking.
“For years the industry has been working to harness the powerful capabilities of cell therapy, but the complexity and variability of working with living cells presents a number of unique challenges,” said Pete van der Wal, president and CEO of HemaCare. “This event will provide attendees with expert insights on developing effective procedures to ensure the best possible research outcomes when using human cells in medical research.”
Moderated by industry thought leader Scott R. Burger, M.D., Chairman of HemaCare Corporation’s Scientific Advisory Board, the event will feature insights from industry luminaries, including:
- Stephen L. Minger, Ph.D., Chief Scientist, Cellular Sciences, GE Healthcare Life Sciences
- Cell Characterization and Quality
- Aby J. Mathew, Ph.D., Senior Vice President and Chief Technology Officer, BioLife Solutions, Inc.
- HemaCare-BioLife Cell Preservation Studies
- Mike Rice, President and CEO, BioLife Solutions, Inc.
- Precision Thermal Packaging Solutions for Cells and Tissues
Event Details:
- Title: Sourcing, Isolating, Preserving, Shipping, and Tracking Precious Human Biological Products: Global Solutions for Research and Cell Therapy
- Date: Thurs., April 24, 12:30-13:30
- Location: Palais des Congrès de Paris, Room 351
- R.S.V.P.: The panel discussion is open to all ISCT attendees and media. To confirm attendance, please contact leslie@apexthink.com
About HemaCare
HemaCare BioResearch Products is a leading blood products and services company serving the scientific community for more than 35 years. HemaCare provides human-derived primary blood cells and tissues for advanced biomedical research, supports cell therapy clinical trials and commercialization with apheresis collections, and provides a wide range of consulting services in SOP development, personnel training, and quality and regulatory compliance. HemaCare´s extensive registry of well-characterized repeat donors, and controlled procedures ensure a readily-available inventory of high-quality, consistent primary human cells and biological products for advanced biomedical research. For more information please visit www.hemacare.com.
